Current Problems in Pediatric and Adolescent Health Care
Volume 36, Issue 10 , Pages 346-376 , November 2006

Sickle Cell Disease—Pathophysiology and Treatment

  • Rupa Redding-Lallinger

      Affiliations

    • Division of Hematology/Oncology, Departments of Pediatrics and Internal Medicine, University of North Carolina, Chapel Hill, NC.
    • ,
  • Christine Knoll

      Affiliations

    • Department of Pediatrics, University of North Carolina, Chapel Hill, NC.

References 

  1. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023–4027
  2. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report (Multicenter investigation of bone marrow transplantation for sickle cell disease). Blood. 2000;95(6):1918–1924
  3. Parise LV, Telen MJ. Erythrocyte adhesion in sickle cell disease. Curr Hematol Rep. 2003;2(2):102–108
  4. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol. 2006;13(1):40–44
  5. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96:314–320
  6. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003;115(9):721–728
  7. Norris CF, Smith-Whitley K, McGowan KL. Positive blood cultures in sickle cell disease: time to positivity and clinical outcome. J Pediatr Hematol Oncol. 2003;25(5):390–395
  8. Barrett-Connor E. Bacterial infection and sickle cell anemia (An analysis of 250 infections in 166 patients and a review of the literature). Medicine (Baltimore). 1971;50(2):97–112
  9. Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in children with sickle cell anemia?. Pediatrics. 1983;71(6):927–931
  10. Wright J, Thomas P, Serjeant GR. Septicemia caused by Salmonella infection: an overlooked complication of sickle cell disease. J Pediatr. 1997;130(3):394–399
  11. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease (Cooperative Study of Sickle Cell Disease). Blood. 1995;86(2):776–783
  12. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease (National Acute Chest Syndrome Study Group). N Engl J Med. 2000;342(25):1855–1865
  13. Atkins BL, Price EH, Tillyer L, Novelli V, Evans J. Salmonella osteomyelitis in sickle cell disease children in the east end of London. J Infect. 1997;34(2):133–138
  14. Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. 1998;101(2):296–297
  15. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed). 1982;285(6342):633–635
  16. Rogers DW, Clarke JM, Cupidore L, Ramlal AM, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell disease. BMJ. 1978;1(6126):1515–1516
  17. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84(6):363–376
  18. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med. 1969;281(17):923–926
  19. Pearson HA, Gallagher D, Chilcote R, Sullivan E, Wilimas J, Espeland M, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics. 1985;76(3):392–397
  20. Emond AM, Morais P, Venugopal S, Carpenter RG, Serjeant GR. Role of splenectomy in homozygous sickle cell disease in childhood. Lancet. 1984;1(8368):88–91
  21. Wright JG, Hambleton IR, Thomas PW, Duncan ND, Venugopal S, Serjeant GR. Postsplenectomy course in homozygous sickle cell disease. J Pediatr. 1999;134(3):304–309
  22. Wilimas JA, Flynn PM, Harris S, Day SW, Smith R, Chesney PJ, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med. 1993;329(7):472–476
  23. Skaggs DL, Kim SK, Greene NW, Harris D, Miller JH. Differentiation between bone infarction and acute osteomyelitis in children with sickle-cell disease with use of sequential radionuclide bone-marrow and bone scans. J Bone Joint Surg Am. 2001;83(12):1810–1813
  24. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol. 2005;129(4):482–490
  25. Lonergan GJ, Cline DB, Abbondanzo SL. Sickle cell anemia. Radiographics. 2001;21(4):971–994
  26. Schmit P, Glorion C. Osteomyelitis in infants and children. Eur Radiol. 2004;14(Suppl 4):L44–L54
  27. Frush DP, Heyneman LE, Ware RE, Bissett GS. MR features of soft-tissue abnormalities due to acute marrow infarction in five children with sickle cell disease. AJR Am J Roentgenol. 1999;173(4):989–993
  28. Umans H, Haramati N, Flusser G. The diagnostic role of gadolinium enhanced MRI in distinguishing between acute medullary bone infarct and osteomyelitis. Magn Reson Imaging. 2000;18(3):255–262
  29. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357(9257):680–683
  30. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia (A randomized trial). N Engl J Med. 1986;314(25):1593–1599
  31. Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143(4):438–444
  32. Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falletta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986;109(4):579–585
  33. Rogers ZR, Buchanan GR. Bacteremia in children with sickle hemoglobin C disease and sickle beta(+)-thalassemia: is prophylactic penicillin necessary?. J Pediatr. 1995;127(3):348–354
  34. Lane PA, O’Connell JL, Lear JL, Rogers ZR, Woods GM, Hassell KL, et al. Functional asplenia in hemoglobin SC disease. Blood. 1995;85(8):2238–2244
  35. Sprinkle RH, Cole T, Smith S, Buchanan GR. Acute chest syndrome in children with sickle cell disease (A retrospective analysis of 100 hospitalized cases). Am J Pediatr Hematol Oncol. 1986;8(2):105–110
  36. Scott-Conner CE, Brunson CD. The pathophysiology of the sickle hemoglobinopathies and implications for perioperative management. Am J Surg. 1994;168(3):268–274
  37. Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, et al. Surgery and anesthesia in sickle cell disease (Cooperative Study of Sickle Cell Diseases). Blood. 1995;86(10):3676–3684
  38. Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood. 1994;83(11):3107–3112
  39. Gelfand MJ, Daya SA, Rucknagel DL, Kalinyak KA, Paltiel HJ. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med. 1993;34(4):614–618
  40. Rucknagel DL. The role of rib infarcts in the acute chest syndrome of sickle cell diseases. Pediatr Pathol Mol Med. 2001;20(2):137–154
  41. Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol. 1999;62(3):129–138
  42. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course (Cooperative Study of Sickle Cell Disease). Blood. 1997;89(5):1787–1792
  43. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease (The Preoperative Transfusion in Sickle Cell Disease Study Group). N Engl J Med. 1995;333(4):206–213
  44. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333(11):699–703
  45. Nordness ME, Lynn J, Zacharisen MC, Scott PJ, Kelly KJ. Asthma is a risk factor for acute chest syndrome and cerebral vascular accidents in children with sickle cell disease. Clin Mol Allergy. 2005;3(1):2
  46. Bryant R. Asthma in the pediatric sickle cell patient with acute chest syndrome. J Pediatr Health Care. 2005;19(3):157–162
  47. Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60(3):206–210
  48. Boyd JH, Moinuddin A, Strunk RC, DeBaun MR. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol. 2004;38(3):229–232
  49. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;May 11
  50. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;May 11
  51. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors (The Cooperative Study of Sickle Cell Disease). Blood. 1994;84(2):643–649
  52. Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child. 1988;142(2):178–182
  53. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81(5):1109–1123
  54. Lanzkowsky P, Shende A, Karayalcin G, Kim YJ, Aballi AJ. Partial exchange transfusion in sickle cell anemia (Use in children with serious complications). Am J Dis Child. 1978;132(12):1206–1208
  55. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92(9):3082–3089
  56. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733–737
  57. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997;87(4):988–990
  58. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001;38(4):333–342
  59. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia (Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia). N Engl J Med. 1995;332(20):1317–1322
  60. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129(4):559–565
  61. Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu HM, Palmor H, et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr Hematol Oncol. 1999;16(3):221–232
  62. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol. 1997;34(3 Suppl 3):42–47
  63. Hankins J, Jeng M, Harris S, Li CS, Liu T, Wang W. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol. 2005;27(3):158–161
  64. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785–789
  65. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease (Life expectancy and risk factors for early death). N Engl J Med. 1994;330(23):1639–1644
  66. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645–1651
  67. Beyer JE, Simmons LE, Woods GM, Woods PM. A chronology of pain and comfort in children with sickle cell disease. Arch Pediatr Adolesc Med. 1999;153(9):913–920
  68. Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease?. J Pain Symptom Manage. 2005;29(4):392–400
  69. Fitzgerald M, Howard R. The neurobiologic basis of pediatric pain. In:  Schechter N,  Berde C,  Yaster M editor. Pain in infants, children, and adolescents. 2nd Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2003;p. 19–42
  70. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79(8):2154–2163
  71. Murray N, May A. Painful crises in sickle cell disease—patients’ perspectives. BMJ. 1988;297(6646):452–454
  72. Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease?. J Pain Symptom Manage. 2005;29(4):392–400
  73. Akinola NO, Stevens SM, Franklin IM, Nash GB, Stuart J. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol. 1992;81(4):598–602
  74. Ballas SK. The acute painful episode. In:  Ballas SK editors. Sickle cell pain. Seattle, WA: IASP Press; 1998;p. 51–89Vol. 11 ed
  75. Stevens MC, Padwick M, Serjeant GR. Observations on the natural history of dactylitis in homozygous sickle cell disease. Clin Pediatr (Phila). 1981;20(5):311–317
  76. Foucan L, Ekouevi D, Etienne-Julan M, Salmi LR, Diara JP. Early onset dactylitis associated with the occurrence of severe events in children with sickle cell anaemia (The Paediatric Cohort of Guadeloupe (1984-99)). Paediatr Perinat Epidemiol. 2006;20(1):59–66
  77. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83–89
  78. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease (Rates and risk factors). N Engl J Med. 1991;325(1):11–16
  79. Dampier C, Ely E, Eggleston B, Brodecki D, O’neal P. Physical and cognitive-behavioral activities used in the home management of sickle pain: a daily diary study in children and adolescents. Pediatr Blood Cancer. 2004;43(6):674–678
  80. Gil KM, Carson JW, Sedway JA, Porter LS, Schaeffer JJ, Orringer E. Follow-up of coping skills training in adults with sickle cell disease: analysis of daily pain and coping practice diaries. Health Psychol. 2000;19(1):85–90
  81. Shapiro BS, Dinges DF, Orne EC, Bauer N, Reilly LB, Whitehouse WG, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain. 1995;61(1):139–144
  82. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease (Rates and risk factors). N Engl J Med. 1991;325(1):11–16
  83. Dampier C, Ely B, Brodecki D, O’Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002;3(6):461–470
  84. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease (Rates and risk factors). N Engl J Med. 1991;325(1):11–16
  85. Armstrong FD, Pegelow C, Gonzalez JC, Martinez A. Impact of children’s sickle cell disease history on nurse and physician ratings of pain and medication decisions. J Pediatr Psychol. 1992;17:651–664
  86. Dampier C, Shapiro B. Management of pain in sickle cell disease. In:  Schechter AN,  Berde C,  Yaster M editor. Pain in infants, children, and adolescents. 2nd Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2003;p. 489–516
  87. American Pain Society. Guideline for the management of acute and chronic pain in sickle cell disease. 1st Edition. 1999;
  88. Beyer JE, Simmons LE. Home treatment of pain for children and adolescents with sickle cell disease. Pain Manag Nurs. 2004;5(3):126–135
  89. Dampier C, Ely B, Brodecki D, O’neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002;3(6):461–470
  90. Gil KM, Anthony KK, Carson JW, Redding-Lallinger R, Daeschner CW, Ware RE. Daily coping practice predicts treatment effects in children with sickle cell disease. J Pediatr Psychol. 2001;26(3):163–173
  91. Hines PC, Zen Q, Burney SN, Shea DA, Ataga KI, Orringer EP, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood. 2003;101(8):3281–3287
  92. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733–737
  93. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63(1):162–169
  94. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 1986;20(6):684–690
  95. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972;287(17):846–849
  96. Kirkham FJ, DeBaun MR. Stroke in children with sickle cell disease. Curr Treat Options Neurol. 2004;6(5):357–375
  97. Buchanan GR, DeBaun MR, Quinn CT, Steinberg MH. Sickle cell disease. Hematology (Am Soc Hematol Educ Program). 2004;35–47
  98. Pavlakis SG, Bello J, Prohovnik I, Sutton M, Ince C, Mohr JP, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol. 1988;23(2):125–130
  99. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139(3):385–390
  100. Moser FG, Miller ST, Bello JA, Pegelow CH, Zimmerman RA, Wang WC, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 1996;17(5):965–972
  101. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis (The Cooperative Study of Sickle Cell Disease). Pediatrics. 1999;103(3):640–645
  102. Powars DR. Natural history of sickle cell disease—the first ten years. Semin Hematol. 1975;12(3):267–285
  103. Adams RJ. Sickle cell disease and stroke. J Child Neurol. 1995;10(2):75–76
  104. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28(3):213–219
  105. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27(4):360–376
  106. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120(3):360–366
  107. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294
  108. NIH. The management of sickle cell disease. 4th Edition. Bethesda, MD: NIH; 2002;
  109. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140(3):348–354
  110. Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19(1):110–129
  111. Wilimas J, Goff JR, Anderson HR, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96(2):205–208
  112. Lusher JM, Haghighat H, Khalifa AS. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol. 1976;1(2):265–273
  113. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461–471
  114. Russell MO, Goldberg HI, Reis L, Friedman S, Slater R, Reivich M, et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J Pediatr. 1976;88(3):382–387
  115. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am J Dis Child. 1979;133(12):1254–1257
  116. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896–899
  117. Okpala I. New therapies for sickle cell disease. Hematol Oncol Clin North Am. 2005;19:975–987
  118. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apheresis. 1999;14(3):122–125
  119. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease (The Cooperative Study of Sickle Cell Disease). Blood. 1990;76(7):1431–1437
  120. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections (The Retrovirus Epidemiology Donor Study). N Engl J Med. 1996;334(26):1685–1690
  121. Hassan M, Hasan S, Giday S, Alamgir L, Banks A, Frederick W, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc. 2003;95(10):939–942
  122. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118(3):377–382
  123. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79(7):1657–1661
  124. Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. J Pediatr. 1992;120(1):54–57
  125. Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346–352
  126. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94(9):3022–3026
  127. Yerys BE, White DA, Salorio CF, McKinstry R, Moinuddin A, DeBaun M. Memory strategy training in children with cerebral infarcts related to sickle cell disease. J Pediatr Hematol Oncol. 2003;25(6):495–498
  128. Cohen MJ, Branch WB, McKie VC, Adams RJ. Neuropsychological impairment in children with sickle cell anemia and cerebrovascular accidents. Clin Pediatr (Phila). 1994;33(9):517–524
  129. Craft S, Schatz J, Glauser TA, Lee B, DeBaun MR. Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr. 1993;123(5):712–717
  130. Armstrong FD, Thompson RJ, Wang W, Zimmerman R, Pegelow CH, Miller S, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease (Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease). Pediatrics. 1996;97(6 Pt. 1):864–870
  131. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;March 8
  132. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104(2):336–339
  133. Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99(8):3014–3018
  134. Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child. 1981;56(10):765–769
  135. Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107(2):201–206
  136. Seeler RA, Shwiaki MZ. Acute splenic sequestration crises (ASSC) in young children with sickle cell anemia (Clinical observations in 20 episodes in 14 children). Clin Pediatr (Phila). 1972;11(12):701–704
  137. Mills ML. Life-threatening complications of sickle cell disease in children. JAMA. 1985;254(11):1487–1491
  138. Pappo A, Buchanan GR. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia. Pediatrics. 1989;84(3):578–579
  139. Mallouh AA, Qudah A. Acute splenic sequestration together with aplastic crisis caused by human parvovirus B19 in patients with sickle cell disease. J Pediatr 193;122(4):593-5.
  140. Powell RW, Levine GL, Yang YM, Mankad VN. Acute splenic sequestration crisis in sickle cell disease: early detection and treatment. J Pediatr Surg. 1992;27(2):215–218
  141. Pearson HA. Sickle cell diseases: diagnosis and management in infancy and childhood. Pediatr Rev. 1987;9(4):121–130
  142. Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990;117(2 Pt. 1):194–199
  143. Koduri PR, Nathan S. Acute splenic sequestration crisis in adults with hemoglobin S-C disease: a report of nine cases. Ann Hematol. 2006;85(4):239–243
  144. Aslam AF, Aslam AK, Dipillo F. Fatal splenic sequestration crisis with multiorgan failure in an adult woman with sickle cell-beta+ thalassemia. Am J Med Sci. 2005;329(3):141–1432005
  145. Aquino VM, Norvell JM, Buchanan GR. Acute splenic complications in children with sickle cell-hemoglobin C disease. J Pediatr. 1997;130(6):961–965
  146. van RF, Balsitis M, French EA. Fatal splenic sequestration crisis in adult sickle cell-beta thalassaemia. Postgrad Med J. 1991;67(792):907–908
  147. Hutchins KD, Ballas SK, Phatak D, Natarajan GA. Sudden unexpected death in a patient with splenic sequestration and sickle cell-beta+-thalassemia syndrome. J Forensic Sci. 2001;46(2):412–414
  148. Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet. 1993;341(8855):1237–1240
  149. Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004;103(2):422–427
  150. Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child. 1987;62(6):585–588
  151. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine (Summary of a workshop). Transfusion. 2001;41(1):130–135
  152. Eichhorn RF, Buurke EJ, Blok P, Berends MJ, Jansen CL. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. J Intern Med. 1999;245(1):103–106
  153. Tolaymat A, Al Mousily F, MacWilliam K, Lammert N, Freeman B. Parvovirus glomerulonephritis in a patient with sickle cell disease. Pediatr Nephrol. 1999;13(4):340–342
  154. Koduri PR, Patel AR, Pinar H. Acute hepatic sequestration caused by parvovirus B19 infection in a patient with sickle cell anemia. Am J Hematol. 1994;47(3):250–251
  155. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004;145(5):617–621
  156. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004;145(5):617–621
  157. Antal P, Gauderer M, Koshy M, Berman B. Is the incidence of appendicitis reduced in patients with sickle cell disease?. Pediatrics. 1998;101(1):E7
  158. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004;145(5):617–621
  159. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(6):518–522
  160. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(6):518–522
  161. Hakim L, Hasmat A, Macchia R. Priapism. In:  Embury SH,  Hebbel RP,  Mohandas N,  Steinberg MH editor. Sickle cell disease: basic Principles and clinical practice. New York: Raven Press; 1994;p. 633–643
  162. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2(8467):1274–1276
  163. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150(5 Pt. 1):1480–1482
  164. Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992;120(6):882–885
  165. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95(1):78–82
  166. Nguyen MT, Ewalt DH, Cavender JD, Buchanan GF, Rogers ZR. Leuprolide therapy in the treatment of sickle cell anemia-associated priapism in adolescents. Blood. 2000;
  167. Jean-Baptiste G, De CK. Osteoarticular disorders of haematological origin. Baillieres Best Pract Res Clin Rheumatol. 2000;14(2):307–323
  168. el-Sabbagh AM, Kamel M. Avascular necrosis of temporomandibular joint in sickle cell disease. Clin Rheumatol. 1989;8(3):393–397
  169. Emodi JI, Okoye IJ. Vertebral bone collapse in sickle cell disease: a report of two cases. East Afr Med J. 2001;78(8):445–446
  170. Sadat-Ali M, Ammar A, Corea JR, Ibrahim AW. The spine in sickle cell disease. Int Orthop. 1994;18(3):154–156
  171. Serjeant GR. Sickle cell disease. 2nd Edition. New York: Oxford University Press; 1992;
  172. Ficat RP. Idiopathic bone necrosis of the femoral head (Early diagnosis and treatment). J Bone Joint Surg Br. 1985;67(1):3–91985.
  173. Adekile AD, Gupta R, Yacoub F, Sinan T, Al-Bloushi M, Haider MZ. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol. 2001;105(1):27–31
  174. Ware HE, Brooks AP, Toye R, Berney SI. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br. 1991;73(6):947–949
  175. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol. 1996;52(2):103–107
  176. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325(21):1476–1481
  177. Aguilar CM, Neumayr LD, Eggleston BE, Earles AN, Robertson SM, Jergesen HE, et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children’s Hospital Oakland Hip Evaluation Scale—a modification of the Harris Hip Score. Arch Phys Med Rehabil. 2005;86(7):1369–1375
  178. Stulberg BN, Davis AW, Bauer TW, Levine M, Easley K. Osteonecrosis of the femoral head (A prospective randomized treatment protocol). Clin Orthop Relat Res. 1991;(268):140–151
  179. Glickstein MF, Burk DL, Schiebler ML, Cohen EK, Dalinka MK, Steinberg ME, et al. Avascular necrosis versus other diseases of the hip: sensitivity of MR imaging. Radiology. 1988;169(1):213–215
  180. Coleman BG, Kressel HY, Dalinka MK, Scheibler ML, Burk DL, Cohen EK. Radiographically negative avascular necrosis: detection with MR imaging. Radiology. 1988;168(2):525–528
  181. Gupta R, Adekile AD. MRI follow-up and natural history of avascular necrosis of the femoral head in Kuwaiti children with sickle cell disease. J Pediatr Hematol Oncol. 2004;26(6):351–353
  182. Zurlo JV. The double-line sign. Radiology. 1999;212(2):541–542
  183. Neumayr L, Robertson S, Aguilar C, Earles AN, Jergesen HE, Haberkern C, et al. Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 3 Year Follow-up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression. Program of the 29th Annual Meeting of the National Sickle Cell Disease Program. 2006.
  184. Hanker GJ, Amstutz HC. Osteonecrosis of the hip in the sickle-cell diseases (Treatment and complications). J Bone Joint Surg Am. 1988;70(4):499–506
  185. Hernigou P, Galacteros F, Bachir D, Goutallier D. Deformities of the hip in adults who have sickle-cell disease and had avascular necrosis in childhood (A natural history of fifty-two patients). J Bone Joint Surg Am. 1991;73(1):81–92
  186. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res. 1993;(289):136–143
  187. Serjeant GR, Ashcroft MT, Serjeant BE. The clinical features of haemoglobin SC disease in Jamaica. Br J Haematol. 1973;24(4):491–501
  188. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–895
  189. De Castro L, Jonassaint JC, Graham FL. Pulmonary hypertension in SS, SC and Sbeta thalassemia: prevalence, associated clinical syndromes, and mortality. Blood. 2006;104:462a
  190. Ambrusko SJ, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediat Blood Cancer. 2006;1–7
  191. Suell MN, Bezold LI, Okcu F, Mahoney D, Shardonfosky F, Mueller BU. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2005;27:654–658
  192. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology. 2005;51–57
  193. Thomas PW, Singhal A, Hemmings-Kelly M, Serjeant GR. Height and weight reference curves for homozygous sickle cell disease. Arch Dis Child. 2000;82(3):204–208
  194. Leonard MB, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA. Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr. 1998;132(3 Pt. 1):467–471
  195. Serjeant GR, Singhal A, Hambleton IR. Sickle cell disease and age at menarche in Jamaican girls: observations from a cohort study. Arch Dis Child. 2001;85(5):375–378
  196. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med. 1984;311(1):7–12
  197. Cipolotti R, Caskey MF, Franco RP, Mello EV, Dal Fabbro AL, Gurgel RQ, et al. Childhood and adolescent growth of patients with sickle cell disease in Aracaju, Sergipe, north-east Brazil. Ann Trop Paediatr. 2000;20(2):109–113
  198. Nelson MC, Zemel BS, Kawchak DA, Barden EM, Frongillo EA, Coburn SP, et al. Vitamin B6 status of children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24(6):463–469
  199. Malinauskas BM, Gropper SS, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA. Impact of acute illness on nutritional status of infants and young children with sickle cell disease. J Am Diet Assoc. 2000;100(3):330–334
  200. Fung EB, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA. Plasma zinc is an insensitive predictor of zinc status: use of plasma zinc in children with sickle cell disease. Nutr Clin Pract. 2002;17(6):365–372
  201. Buison AM, Kawchak DA, Schall J, Ohene-Frempong K, Stallings VA, Zemel BS. Low vitamin D status in children with sickle cell disease. J Pediatr. 2004;145(5):622–627
  202. Barden EM, Zemel BS, Kawchak DA, Goran MI, Ohene-Frempong K, Stallings VA. Total and resting energy expenditure in children with sickle cell disease. J Pediatr. 2000;136(1):73–79

PII: S1538-5442(06)00074-5

doi: 10.1016/j.cppeds.2006.07.002

Current Problems in Pediatric and Adolescent Health Care
Volume 36, Issue 10 , Pages 346-376 , November 2006

Article Tools

* Image Usage & Resolution